Hughes Center Makes Groundbreaking ProArgi-9+ Discoveries

Scientists at the Hughes Center for Research and Innovation have made several remarkable discoveries on Synergy’s ProArgi-9+ formula, showing that ProArgi-9+ can do what l-arginine cannot do on its own. Following these discoveries, Nature’s Sunshine has filed a United States provisional patent application to ensure that Synergy maintains exclusive rights to this iconic formula.

While the details of the patent application are not yet published, Dr. Matthew Tripp, Nature’s Sunshine’s Chief Scientific Officer, shared some insights into their discoveries.

“Numerous studies have shown the cardiovascular benefits of l-arginine,” explained Nature’s Sunshine’s Chief Scientific Officer, Dr. Matthew Tripp. “However, our preliminary in vitro and human studies showed that the unique combination of ingredients in our ProArgi-9+ formula enhances the effects of L-arginine within the body in several ways.”


The body converts the amino acid l-arginine into nitric oxide to support healthy circulatory and cardiovascular function. Although l-arginine alone can increase the surrogate marker of saliva nitric oxide, this is a gradual process. In testing ProArgi-9+, Nature’s Sunshine found that its formula significantly and rapidly increases the level of nitric oxide in the body.

The findings of this study are significant because other studies show that aging and poor diet can affect the metabolic systems responsible for producing nitric oxide, causing them to work less effectively. Healthy nitric oxide levels are important for proper vasodilation, along with blood pressure, muscle, heart and central nervous system function*.


Previous studies have shown that l-arginine has no significant effect on myeloperoxidase, an enzyme that inhibits nitric oxide production. Additionally, l-arginine has no significant influence on inhibiting the oxidation of LDL cholesterol. The Hughes Center’s preliminary study discovered that the unique combination of ingredients found in Synergy’s ProArgi-9+ potently inhibited myeloperoxidase and helps to reduce the oxidation of LDL cholesterol.

“These groundbreaking studies are exactly what we hoped for when the Hughes Center opened its doors in February 2015,” said Dan Norman, President of Synergy WorldWide. “Thanks to Dr. Matthew Tripp and his team of skilled scientists, we can publicize the proven impact ProArgi-9+ can have on countless lives all over the world. This is exciting news, and we are eager to share it with individuals around the world with the hope of helping more people achieve optimal health.”

Together, the results of these studies indicate that the unique properties found in ProArgi-9+ positively impact cardiovascular health by supporting the production of nitric oxide and inhibiting myeloperoxidase. These findings support the use of ProArgi-9+ for optimal heart health.

The Hughes Center is revealing the power that lies in Synergy products. Synergy WorldWide is incredibly fortunate to have a brilliant and seasoned staff of scientists standing behind its products, providing telling research that reinforces Synergy’s mission to leave a lasting legacy of health around the world.

CLICK HERE for the official press release.
For a downloadable version of the press release, CLICK HERE.




Follow Us